Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial

NCT05947500 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05947500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 21, 2024
Completion date
January 1, 2028
Enrollment
50 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous merkel cell carcinoma ajcc v8, clinical stage iv cutaneous merkel cell carcinoma ajcc v8, locally advanced merkel cell carcinoma, metastatic merkel cell carcinoma, refractory merkel cell carcinoma, unresectable merkel cell carcinoma